Back to the Homepage
 |
Phase I-II trial to asses the dose limiting toxicity, tolerance and efficacy of hemi-synthetic homoharringtonine (Myelostat®) in combination with imatinib mesylate (Glivec®) in patients with chronic myeloid leukemia after cytogenetic failure with Glivec®. Investigator Coordinator : Prof F. Guilhot CHU Poitiers France |
|
A phase II multicentre, single-arm, open-label study of subcutaneous hemi-synthetic homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have relapsed on imatinib mesylate Protocol : HHT-CML/INTL/04.2 Investigator Coordinator : Dr Frederic Maloisel CHU Strasbourg France - Dr David Marin, Hammersmith Hospital, London UK |
Investigators’ ongoing clinical trials:
|
Semi-synthetic homoharringtonine (Myelostat©) for CML patients in accelerated phase after imatinib failure. Contact: Dr David Marin - Catherine Lewis Centre - Hammersmith Hospital, Du Cane Road, London W12 0HS) Investigator Coordinator : Prof F. Guilhot CHU Poitiers France |
|
Semi-synthetic homoharringtonine (Myelostat©) in combination with imatinib for CML patients who have achieved partial or complete cytogenetic responses. Contact: Dr David Marin - Catherine Lewis Centre - Hammersmith Hospital, Du Cane Road, London W12 0HS) |
